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Small bowel capsule endoscopy in obscure gastrointestinal
bleeding: normalcy is not reassuring
Tiago Cúrdia Gonçalvesa, Francisca Dias de Castroa, Maria João. Moreiraa,
Bruno Rosaa and José Cottera,b,c
Background/Aim Small bowel capsule endoscopy
(SBCE) is currently a fundamental tool in the etiological
study of obscure gastrointestinal bleeding (OGIB).
However, the impact of a negative exam and the risk of
rebleeding are not entirely known. The aim of this study was
to evaluate the outcomes of patients with OGIB and a
negative SBCE examination in terms of follow-up duration,
additional diagnostic studies, and achievement of a
diagnosis as well as to assess the incidence of rebleeding
and possible associated factors.
Materials and methods We retrospectively analyzed 256
patients who consecutively underwent an SBCE
examination for the study of OGIB between April 2006 and
December 2011, and then selected the 79 whose results
excluded potentially bleeding lesions. Eleven patients were
lost to follow-up and the remaining 68 were eligible for a
nested case–control analysis. Pre-SBCE and post-SBCE
information was collected, including follow-up interval and
incidence of rebleeding, defined as admission to the
hospital for symptomatic anemia, need for blood
transfusion, decrease in hemoglobin value of greater than
2 g/dl, or evidence of melena or hematochezia. Univariate
analysis included age, sex, OGIB presentation (occult or
visible), hemoglobin levels at presentation, and
comorbidities.
Results In the 68 patients analyzed, the mean age was
52±18 years and 61.8% were women. The OGIB was occult
in 54 patients (79.4%) and overt in 14 patients (20.6%).
Patients were followed up for an average of 32 months.
Thirty-nine patients (57.4%) underwent further diagnostic
investigations during the period of follow-up and a cause for
the gastrointestinal bleeding was found in five of them.
Rebleeding was documented in 16 (23.5%) patients,
occurring on average 15±13.8 months after the SBCE. Male
sex was associated significantly with higher incidence of
rebleeding (P= 0.004).
Conclusion Approximately one quarter of patients with
OGIB and negative SBCE examination will experience
rebleeding, with higher incidence among men; thus, a
negative SBCE in this setting is not reassuring. As the vast
majority of rebleeding episodes seem to occur within the
following 2 years after SBCE, the maintenance of regular
medical surveillance during the above-mentioned period of
time after a negative SBCE seems advisable. Eur J
Gastroenterol Hepatol 00:000–000 © 2014 Wolters Kluwer
Health | Lippincott Williams & Wilkins.
European Journal of Gastroenterology & Hepatology 2014, 00:000–000
Keywords: capsule endoscopy, obscure gastrointestinal bleeding,
rebleeding, small bowel
aGastroenterology Department, Centro Hospitalar do Alto Ave, Guimarães, bLife
and Health Sciences Research Institute, University of Minho, Braga/Guimarães,
and cICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães,
Portugal
Correspondence to Tiago Cúrdia Gonçalves, MD, Gastroenterology Department,
Centro Hospitalar do Alto Ave, Rua dos Cutileiros, Creixomil 4835-044
Guimarães, Portugal
Tel: +351 253 540 330; fax: +351 253 513 592;
e-mail: tiagogoncalves@chaa.min-saude.pt
Received 2 March 2014 Accepted 2 May 2014
Introduction
Obscure gastrointestinal bleeding (OGIB), which repre-
sents almost 5% of all gastrointestinal (GI) hemorrhage
and 30% of all cases of iron-deficiency anemia, remains a
diagnostic and therapeutic challenge for gastro-
enterologists [1,2]. It is defined as bleeding from the GI
tract that persists or recurs without an obvious etiology
after esophagogastroduodenoscopy and colonoscopy [3].
OGIB may present in the form of occult OGIB (positive
fecal occult blood test or iron-deficiency anemia) or overt
OGIB (passage of visible blood) [3].
When the origin of bleeding is located in the small bowel,
which occurs in 75% of cases of OGIB [4], patients tend
to undergo more diagnostic procedures, have longer
hospital stays, require more blood transfusions, and have
associated higher healthcare costs when compared with
patients with colonic or upper GI bleeding [5].
Small bowel capsule endoscopy (SBCE) is currently
recommended as a first-line diagnostic study for the
etiological investigation of OGIB [6], which remains the
most common indication for this procedure [4,7]. In
addition to being safe, noninvasive, and well tolerated,
several studies have confirmed that SBCE has a higher
diagnostic yield in identifying the cause of OGIB than
other procedures such as push enteroscopy, small bowel
barium radiography, computer tomography enteroclysis,
mesenteric angiography, intraoperative enteroscopy, or
magnetic resonance enteroclysis [8].
Despite its high diagnostic yield [9,10], in about 20–40%
of patients with clinical OGIB subjected to SBCE, no
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lesions are identified [11]. As guidelines for this specific
situation are lacking and most studies include not
only a small number of patients but also short-term
follow-up, the long-term outcomes of these patients
remain unclear.
The primary aim of this study was to evaluate the out-
comes of patients with OGIB and a nondiagnostic SBCE
examination, namely, duration of follow-up, performance
of additional diagnostic studies, and achievement of a
diagnosis. We also aimed to report the rate of rebleeding
in this subset of patients and to identify possible asso-
ciated risk factors.
Materials and methods
Patients and study design
This study was a single-center retrospective nested
case–control investigation. All patients referred to our
center for the etiologic study of OGIB with SBCE
between April 2006 and December 2011 were included.
Following the definition of OGIB [3], all patients
underwent nondiagnostic esophagogastroduodenoscopy
and colonoscopy before referral for SBCE. Furthermore,
women were evaluated to exclude abnormal gynecolo-
gical bleeding. Patients’ clinical information was col-
lected from medical records, including sex, age, type of
presentation of OGIB, hemoglobin levels, clinical history,
and medical therapy. Patients whose SBCE examination
was incomplete (capsule not reaching the cecum within
reading time) were not included.
SBCE procedure
SBCE was performed using PillCam SB or PillCam SB2
capsules from GIVEN Imaging (Yoqneam, Israel).
Patients received a clear liquid diet the day before cap-
sule ingestion and an overnight 12 h fast. Patients were
allowed to drink fluids after 2 h and to have a light meal
after 4 h of capsule ingestion. Informed consent was
obtained from every patient before SBCE. Consensual
contraindications for the SBCE procedure were respec-
ted and have been described elsewhere [12].
Analysis of SBCE findings
The complete video obtained in each SBCE was
reviewed by two gastroenterologists experienced with
the use of capsule endoscopy. In case of no interobserver
agreement, the findings were reviewed by both gastro-
enterologists and a consensus was reached. Lesions were
classified according to their bleeding potential using the
system reported by Saurin et al. [13]. Three categories of
lesions were considered: P0 lesions, such as visible sub-
mucosal veins, nodules without mucosal break, or
diverticula without the presence of blood, were assumed
to have no bleeding potential. P1 lesions, namely,
mucosal erosions or mucosal red spots were considered to
have uncertain bleeding potential. P2 lesions, including
typical angiomata, tumors, large ulcerations, or varices,
were considered to have high bleeding potential. In our
study, SBCE examination was considered positive when
P2 lesions were found, whereas P1 or P0 lesions and
normal recordings were classified as negative SBCE
examination. The diagnostic yield of SBCE was defined
as the ratio of the number of cases with small bowel
findings responsible for OGIB (namely P2 lesions) to the
total number of cases of OGIB subjected to SBCE.
Patients’ follow-up
Follow-up data were obtained by reviewing the medical
records. Rebleeding was defined as evidence of symp-
tomatic anemia, need for blood transfusion, decrease in
hemoglobin value of greater than 2 g/dl, or evidence of
melena, or hematochezia with nondiagnostic upper and
lower GI endoscopy when performed. We assessed the
interval of follow-up after SBCE for each patient, the
occurrence, and timing of rebleeding episodes; additional
studies were carried out for the investigation of OGIB
and definite diagnosis.
Data analysis
Statistical analysis was carried out using the statistical
packages for social sciences software, version 17.0 (IBM,
Armonk, New York, USA). Quantitative data, namely age
and hemoglobin value, were expressed as mean ± SD.
Univariate analysis between cases (patients with
rebleeding during the follow-up) and controls (patients
without new rebleeding episodes) was carried out. As age
had a normal distribution, a parametric statistic (Student’s
t-test) was used. Hemoglobin values did not have a
normal distribution and a nonparametric statistic
(Mann–Whitney test) was applied. For nominal variables,
the χ2-test or Fisher’s exact test was used as appropriate.
Statistical significance was considered when the P value
was less than 0.05.
Results
Patients’ description
Between April 2006 and December 2011, a total of 256
patients underwent SBCE in our center for etiologic
investigation of OGIB. No complications related to the
procedure occurred. In 177 of these patients (69.1%),
SBCE examination identified the lesions responsible for
the GI bleeding. However, in the remaining 79 patients
(30.9%), SBCE examination was negative. From the 79
patients selected to enter this study, 11 had been sent
from other hospitals or primary care centers and as
additional clinical data were unavailable, they were
excluded from the study analysis (Fig. 1). Among the
remaining 68 patients, five had P1 lesions on SBCE
(small bowel erosions), one had P0 lesions (visible sub-
mucosal veins), and the remaining 62 patients had normal
SBCE. From the analyzed patients, 42 (61.8%) were
women, and the mean age was 52 ± 18 years, ranging
between 21 and 85 years. The indication for SBCE
examination was occult OGIB in 54 patients (79.4%),
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whereas only 14 patients (20.6%) had overt OGIB.
Baseline characteristics are summarized in Table 1.
Patients’ follow-up
Medical records of the follow-up were available for 68
patients (Fig. 1). The follow-up interval was largely
variable between patients, with a mean of 32 ± 21
months, ranging from 1 to 83.
During follow-up, a total of 39 patients (57.4%) were
subjected to further GI investigations to find a definitive
diagnosis to explain the OGIB. These investigations
included 44 second-look esophagogastroduodenoscopies,
36 colonoscopies, six SBCEs, seven nuclear scans, and
one small bowel series. According to the policy at our
center, deep enteroscopy was not used in any patient
with negative capsule endoscopy.
In five patients (7.4%), a cause for the OGIB was found
on subsequent examinations after SBCE, including two
patients with angioectasias in the ascending colon,
two patients with celiac disease, and one patient with
colon cancer. All these patients received specific treat-
ment for their condition, namely, argon plasma
coagulation for angioectasias, a gluten-free diet for celiac
disease, and right hemicolectomy for colon cancer.
Rebleeding
Episodes of rebleeding, as defined above, were mon-
itored during the follow-up. Sixteen patients (23.5%) had
at least one rebleeding episode and the mean time
interval between the SBCE and rebleeding was
15 ± 13.8 months, ranging from 1 to 51 months.
Remarkably, rebleeding occurred in the first year after
SBCE in 10 patients (62.5%), and in 13 patients (81.3%)
it occurred within the first 2 years after SBCE.
We investigated factors that could possibly be associated
with a higher risk of rebleeding, namely, sex, patients’
age, indication for SBCE, antithrombotic drugs, as well as
some common comorbidities such as hypertension,
hypercholesterolemia, diabetes mellitus, chronic liver
disease, or chronic kidney disease. Rebleeding was sig-
nificantly more common in men (68.8 vs. 31.2%;
P= 0.004). Anticoagulant drug users also seemed at a
higher risk of developing rebleeding, but this was not









29 patients without additional
diagnostic studies
(5 overt; 24 occult)
39 patients with additional
diagnostic studies




(7 overt; 27 occult)
5 patients with a
diagnosis
(2 visible; 3 occult)
Specific treatment
Patients’ follow-up. OGIB, obscure gastrointestinal bleeding; SBCE, small bowel capsule endoscopy.
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were not statistically different between patients with and
without rebleeding and are summarized in Table 1.
Discussion
Since its appearance in 2000, SBCE has become an
essential tool for the investigation of the small bowel [14].
For OGIB, which remains the most common indication
for SBCE, the examination has a considerably high
diagnostic yield, varying between 45 and 75% [15].
However, a significant proportion of patients presenting
with occult or overt OGIB have nondiagnostic SBCE
examinations, making the management of this topic even
more challenging. The impact of negative small bowel
examinations on the patients’ outcome, namely risk of
rebleeding, is currently under debate and the optimal
approach in these situations is far from well defined.
What is the rebleeding rate in these patients? What is the
acceptable follow-up interval? Which patients are at an
increased risk of rebleeding? These are some of the
questions whose answers remain controversial.
In this study, although 16 patients (23.5%) were mon-
itored for less than 1 year, the remaining 52 (76.5%) had
long-term follow-up intervals, varying from 12 to
83 months. The mean interval of follow-up was
32 months, which is one of the longest described in the
literature. Some studies have shown the results of
patients monitored during 1 year [2], whereas others
showed results of longer intervals, [11,16–19] but the
appropriate follow-up interval of patients with OGIB
after negative SBCE remains unclear.
During the follow-up interval, either because there was a
lack of a definitive diagnosis or because rebleeding
occurred, some patients were subjected to additional
examinations. According to the literature, it is not rare to
find possible causative lesions when further investiga-
tions are performed and several different lesions have
been described. Such lesions include Dieulafoy’s,
diverticula, small bowel ulcers, lymphomas, angioectasias
(gastric, intestinal, or colonic), hiatus hernia ulcerations
(Cameron’s lesions), Meckel’s diverticula, GI stromal
tumors, small bowel adenocarcinomas, carcinoid tumors,
arteriovenous malformations, or aorto-enteric fistulas [2,9,
11,17,18,20]. One study reported that patients with
OGIB and a lesion seen on SBCE still could have an
undiscovered lesion within the reach of conventional
scopes in up to 15% of patients [21]. Although there is no
consensus on the number of upper endoscopies and
colonoscopies before patients undergo SBCE, some
authors consider SBCE after two negative investigations
[22,23]. In our study, patients underwent SBCE after one
negative upper endoscopy and colonoscopy and the
results showed that all of the five patients with OGIB and
negative SBCE, who received a final diagnosis at follow-
up, had lesions that were in the reach of upper endoscopy
and colonoscopy. These findings may indicate that
second-look upper endoscopies and colonoscopies could
be considered after negative SBCE.
The techniques that can be used to further assess these
patients include device-assisted enteroscopy, radiologic
studies, or intraoperative enteroscopy [24]. Some authors
have suggested that a subgroup of patients (especially
those who changed presentation from occult to overt
OGIB and those with a decrease in hemoglobin of 4 g/dl
or more) could benefit from a second-look SBCE [15]. In
our study, however, only six patients were subjected to a
second-look SBCE examination, which was again non-
diagnostic in all of those cases. These results were
slightly disappointing, considering the increased costs of
repeating SBCE.
Independent of the presence or absence of further
investigation after a negative SBCE, patients with OGIB
are at risk of having rebleeding episodes. However, the
rate of rebleeding during the follow-up is highly variable,
ranging from 0% [2] up to 50% [25], as summarized in
Table 2. In our study, we found an intermediate
rebleeding rate of 23.5%, which is comparable with sev-
eral other studies [18,27,28]. The discrepancies found on
rebleeding rates in the literature might be explained by
differences in patients’ selection and subsequent man-
agement as well as by different follow-up intervals. The
timing of the rebleeding episodes after a negative SBCE




rebleeding With rebleeding Total [n (%)] P
Mean age (years) 50.3 ± 17.8 56.7 ±19.9 – 0.217
Sex
Male 15 11 26 (38.2) 0.004*
Female 37 5 42 (61.8)
Indication for SBCE
Occult OGIB 40 14 54 (79.4) 0.492
Overt OGIB 12 2 14 (20.6)
Hypertension
No 31 9 40 (58.8) 0.811
Yes 21 7 28 (41.2)
Dyslipidemia
No 34 10 44 (64.7) 0.833
Yes 18 6 24 (35.3)
Diabetes mellitus type 2
No 40 13 53 (77.9) 1.000
Yes 12 3 15 (22.1)
Chronic liver disease
No 50 14 64 (94.1) 0.233
Yes 2 2 4 (5.9)
Chronic kidney disease
No 45 14 59 (86.8) 1.000
Yes 7 2 9 (13.2)
Mean hemoglobin
value (g/dl)
10.6 ±1.9 10.9 ±2.1 – 0.303
Antiplatelet drug use
No 35 9 44 (64.7) 0.418
Yes 17 7 24 (35.3)
Anticoagulant drug use
No 48 12 60 (88.2) 0.081
Yes 4 4 8 (11.8)
OGIB, obscure gastrointestinal bleeding; SBCE, small bowel capsule endoscopy.
*Statistically significant.
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examination has not been investigated extensively in the
literature, but intervals ranging from 1 to 13.8 months
have been reported [11,16], whereas in our series, we
found a longer mean time interval of 15 months between
the SCBE procedure and the rebleeding episode.
A secondary outcome of our study was to evaluate pos-
sible factors associated with the risk of rebleeding in
patients with OGIB and nondiagnostic SBCE examina-
tion. This topic has scarcely been explored in previous
studies. We found the male sex to be significantly asso-
ciated with rebleeding episodes after a negative SBCE.
Moreover, similar to what has been reported before [18,
19], anticoagulant drug use was also marginally associated
with rebleeding episodes in these patients, although not
reaching statistical significance. Unlike what has been
reported previously [17], we found no association
between age or the indication for the SBCE (overt or
occult OGIB) and the occurrence of rebleeding episodes
during follow-up.
Conclusion
Our study represents one of the largest series in the lit-
erature of patients having OGIB and negative SBCE
examinations (Table 2). We have shown that although
some patients may benefit from a more exhaustive
attempt to clarify the etiology of OGIB, in approximately
three quarters of cases, patients with OGIB and negative
SBCE do not seem to be at an increased risk of adverse
outcomes and may be safely followed with no need for
further investigations or interventions. Nonetheless,
even when SBCE shows no potentially bleeding lesions,
almost one quarter of patients, particularly men, are likely
to experience an episode of rebleeding when followed up
for longer periods. In the absence of stringent guidelines
for patients with OGIB and nondiagnostic SBCE, and
taking into account the present results, it seems reason-
able to assume that these patients are still at risk of
rebleeding and a close monitoring for recurrence of
bleeding episodes is required. The appropriate duration
of follow-up is unclear, but in view of our results, patients
may benefit from close follow-up for at least 2 years,
which, in our experience, will cover about 80% of the
episodes of rebleeding.
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